The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Open accessAbstract
BACKGROUND: Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study. METHODS: In a double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients with very-low-risk, low-risk, or intermediate-risk myelodysplastic syndromes (defined according to the Revised International Prognostic Scoring System) with ring sideroblasts who had been receiving regular red-cell transfusions to receive either luspatercept (at a dose of 1.0 up to 1.75 mg per kilogram of body weight) or placebo, administered subcutaneously every 3 weeks. The primary end point was transfusion independence for 8 weeks or longer during weeks 1 through 24, and the key secondary end point was transfusion independence for 12 weeks or longer, assessed during both weeks 1 through 24 and weeks 1 through 48. RESULTS: Of the 229 patients enrolled, 153 were randomly assigned to receive luspatercept and 76 to receive placebo; the baseline characteristics of the patients were balanced. Transfusion independence for 8 weeks or longer was observed in 38% of the patients in the luspatercept group, as compared with 13% of those in the placebo group (P<0.001). A higher percentage of patients in the luspatercept group than in the placebo group met the key secondary end point (28% vs. 8% for weeks 1 through 24, and 33% vs. 12% for weeks 1 through 48; P<0.001 for both comparisons). The most common luspatercept-associated adverse events (of any grade) included fatigue, diarrhea, asthenia, nausea, and dizziness. The incidence of adverse events decreased over time. CONCLUSIONS: Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event. (Funded by Celgene and Acceleron Pharma; MEDALIST ClinicalTrials.gov number, NCT02631070; EudraCT number, 2015-003454-41.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Self-citationInternational scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationVardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationInterpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Self-citationCheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,032
Self-citationMalcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Self-citationMalcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Self-citationCheson, B. D., Bennett, J. M., Kantarjian, H. M., Pinto, A., Schiffer, C. A., Nimer, S. D., Löwenberg, B., Beran, M., de Witte, T. M., Stone, R. M., et al. (2000) · PubMed · Cited by 666
Self-citationInterim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cocks, K., King, M. T., Velikova, G., de Castro, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.059 · Cited by 552
Anemia at older age: etiologies, clinical implications, and management
Stauder, R., Valent, P., & Theurl, I. (2018) · Blood · doi:10.1182/blood-2017-07-746446 · Cited by 479
Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 445
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Self-citationPark, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.-T., et al. (2008) · Blood · doi:10.1182/blood-2007-06-096370 · Cited by 334
Self-citationPlatzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30615-0 · Cited by 292
Self-citationPlatzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-10-844696 · Cited by 235
Self-citationSantini, V., Almeida, A., Giagounidis, A., Gröpper, S., Jonasova, A., Vey, N., Mufti, G. J., Buckstein, R., Mittelman, M., Platzbecker, U., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.0118 · Cited by 215
Self-citationInhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS
Zhou, L., Nguyen, A. N., Sohal, D., Ying Ma, J., Pahanish, P., Gundabolu, K., Hayman, J., Chubak, A., Mo, Y., Bhagat, T. D., et al. (2008) · Blood · doi:10.1182/blood-2008-02-139824 · Cited by 184
Self-citationFenaux, P., Santini, V., Spiriti, M. A. A., Giagounidis, A., Schlag, R., Radinoff, A., Gercheva-Kyuchukova, L., Anagnostopoulos, A., Oliva, E. N., Symeonidis, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0118-9 · Cited by 163
Self-citationPredicting survival and leukemic evolution in patients with myelodysplastic syndrome.
Malcovati, L., Porta, M. G. D., & Cazzola, M. (2006) · PubMed · Cited by 161
Self-citationSuragani, R. N. V. S., Cawley, S. M., Li, R., Wallner, S., Alexander, M. J., Mulivor, A. W., Gardenghi, S., Rivella, S., Grinberg, A. V., Pearsall, R. S., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511238 · Cited by 152
How we treat lower-risk myelodysplastic syndromes
Fenaux, P., & Adès, L. (2013) · Blood · doi:10.1182/blood-2013-02-453068 · Cited by 150
Self-citationTehranchi, R., Fadeel, B., Forsblom, A., Christensson, B., Samuelsson, J., Zhivotovsky, B., & Hellström‐Lindberg, E. (2003) · Blood · doi:10.1182/blood-2002-06-1774 · Cited by 133
Self-citationToma, A., Kosmider, O., Chevret, S., Delaunay, J., Stamatoullas, A., Rosé, C., Beyne‐Rauzy, O., Baños, A., Guerci‐Bresler, A., Wickenhauser, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.296 · Cited by 126
Self-citationTehranchi, R. (2005) · Blood · doi:10.1182/blood-2004-12-4649 · Cited by 104
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis
Fenaux, P., Kiladjian, J., & Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-11-876888 · Cited by 104
Self-citationPark, S., Hamel, J.-F., Toma, A., Kelaïdi, C., Thépot, S., Díez‐Campelo, M., Santini, V., Sekeres, M. A., Balleari, E., Kaivers, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3271 · Cited by 98
Self-citationSantini, V., Schemenau, J., Levis, A., Balleari, E., Sapena, R., Adès, L., Guerci‐Bresler, A., Beyne‐Rauzy, O., Gourin, M.-P., Chèze, S., et al. (2013) · Blood · doi:10.1182/blood-2013-07-512442 · Cited by 79
Self-citationThe role of TGFβ in hematopoiesis and myeloid disorders
Bataller, Á., Bravo, G. M., Soltysiak, K. A., & Garcia‐Manero, G. (2019) · Leukemia · doi:10.1038/s41375-019-0420-1 · Cited by 77
Self-citationKelaïdi, C., Park, S., Sapena, R., Beyne‐Rauzy, O., Coiteux, V., Vey, N., Stamatoullas, A., Choufi, B., Delaunay, J., Gourin, M. P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.16 · Cited by 69
Self-citationGuerra, A., Oikonomidou, P. R., Sinha, S., Zhang, J., Presti, V. L., Hamilton, C. R., Breda, L., Casu, C., La, P., Martins, A. C., et al. (2019) · Blood · doi:10.1182/blood.2019001057 · Cited by 66
Self-citationBiological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes
Verma, A. K., Suragani, R. N. V. S., Aluri, S., Shah, N. N., Bhagat, T. D., Alexander, M. J., Komrokji, R. S., & Kumar, R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133678 · Cited by 64
Self-citationThépot, S., Abdelali, R. B., Chevret, S., Renneville, A., Beyne‐Rauzy, O., Prébet, T., Park, S., Stamatoullas, A., Guerci‐Bresler, A., Chèze, S., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140988 · Cited by 62
Self-citationPinchon, D. J., Stanworth, S. J., Doree, C. J., Brunskill, S. J., & Norfolk, D. R. (2009) · American Journal of Hematology · doi:10.1002/ajh.21503 · Cited by 59
Tobiasson, M., Dybedahl, I., Holm, M. S., Karimi, M., Brandefors, L., Garelius, H. G., Grövdal, M., Dufva, I. H., Grønbæk, K., Jansson, M., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.8 · Cited by 56
Self-citationLenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Talati, C., Sallman, D. A., & List, A. F. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.003 · Cited by 45
Self-citationA review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes.
Olíva, E. N., Schey, C., & Hutchings, A. (2011) · PubMed Central · Cited by 34
Abel, G. A., Klaassen, R. J., Lee, S. J., Young, N. L., Cannella, L., Steensma, D. P., & Efficace, F. (2014) · Blood · doi:10.1182/blood-2013-11-540021 · Cited by 30
Red Bood Cell Transfusion Therapy and Iron Chelation in Patients With Myelodysplastic Syndromes
Malcovati, L. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.029 · Cited by 20
Rewriting the rules for care of MDS and AML patients in the time of COVID-19
Raza, A., Assal, A., Ali, A. M., & Jurcic, J. G. (2020) · Leukemia Research Reports · doi:10.1016/j.lrr.2020.100201 · Cited by 20
Self-citationGDF11 is not the target of luspatercept
Camaschella, C. (2019) · Blood · doi:10.1182/blood.2019001983 · Cited by 16
Cited by
Zeidan, A. M., Boddu, P. C., Patnaik, M. M., Bewersdorf, J. P., Stahl, M., Rampal, R. K., Shallis, R., Steensma, D. P., Savona, M. R., Sekeres, M. A., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30205-2 · Cited by 675
Self-citationNovel therapies emerging in oncology to target the TGF‐β pathway
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26857 · Cited by 305
Malcovati, L., Stevenson, K., Papaemmanuil, E., Neuberg, D., Bejar, R., Boultwood, J., Bowen, D. T., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 297
Self-citationInnate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
Metadata
- Authors
- Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Cazzola, M., Ilhan, O., Sekeres, M. A., Falantes, J. F., Arrizabalaga, B., Salvi, F., Giai, V., Vyas, P., Bowen, D., Selleslag, D., DeZern, A. E., Jurcic, J. G., Germing, U., Götze, K. S., Quesnel, B., Beyne-Rauzy, O., Cluzeau, T., Voso, M.-T., Mazure, D., Vellenga, E., Greenberg, P. L., Hellström-Lindberg, E., Zeidan, A. M., Adès, L., Verma, A., Savona, M. R., Laadem, A., Benzohra, A., Zhang, J., Rampersad, A., Dunshee, D. R., Linde, P. G., Sherman, M. L., Komrokji, R. S., & List, A. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-09
- Volume
- 382
- Issue
- 2
- Pages
- 140-151
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2998901800
- Cited by
- 550
- References
- 43
- FWCI
- 46.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.